Please assess the completion status of the following clinical trial:

Trial Title: hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed neuroblastoma~* Relapsed or refractory to conventional therapy~* Measurable or evaluable disease documented by 1 of the following criteria:~  * Clinical~ * Radiographic~ * Histologic~ * MIBG (meta-iodobenzylguanidine) scanning~ * Immunocytochemistry~* No symptomatic pleural effusions or ascites requiring constant or intermittent drainage~* No clinical or radiological evidence of central nervous system (CNS) disease~PATIENT CHARACTERISTICS:~Age~* 21 and under~Performance status~* Karnofsky 50-100% (\> 16 years of age)~* Lansky 50-100% (≤ 16 years of age)~Life expectancy~* At least 8 weeks~Hematopoietic~* Absolute neutrophil count \> 1,000/mm\^3~* Platelet count ≥ 75,000/mm\^3\*~  * Must not be refractory to platelet transfusions~* Hemoglobin ≥ 9.0 g/dL\* NOTE: \*Transfusion allowed if patient is known to have a history of bone marrow involvement with tumor~Hepatic~* Alanine transaminase (ALT) \< 2.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* Hepatitis B surface antigen negative~Renal~* Creatinine adjusted according to age as follows:~  * No greater than 0.4 mg/dL (≤ 5 months)~ * No greater than 0.5 mg/dL (6 months -11 months)~ * No greater than 0.6 mg/dL (1 year-23 months)~ * No greater than 0.8 mg/dL (2 years-5 years)~ * No greater than 1.0 mg/dL (6 years-9 years)~ * No greater than 1.2 mg/dL (10 years-12 years)~ * No greater than 1.4 mg/dL (13 years and over \[female\])~ * No greater than 1.5 mg/dL (13 years to 15 years \[male\])~ * No greater than 1.7 mg/dL (16 years and over \[male\]) OR~* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min~Cardiovascular~* Shortening fraction ≥ 27% by echocardiogram OR~* Ejection fraction ≥ 50% by Multi Gated Acquisition Scan (MUGA)~* No symptomatic congestive heart failure~* No uncontrolled cardiac rhythm disturbance~Pulmonary~* Pulse oximetry \> 94% on room air~* Forced vital capacity (FVC) \> 80%~* Forced expiratory volume (FEV_1) \> 80%~* No abnormal respiratory function~* No dyspnea at rest~* No exercise intolerance~* No prior history of ventilator support related to lung injury (e.g., pneumonia, hemorrhagic pneumonitis, or capillary leakage)~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* No active uncontrolled infection~* No active uncontrolled peptic ulcer~* No objective peripheral neuropathy ≥ grade 2~* No significant psychiatric disabilities~* No seizure disorders requiring antiseizure medications~* No other concurrent significant illness~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Recovered from prior immunotherapy~* Prior in vivo monoclonal antibodies for biologic therapy or tumor imaging allowed provided there is documented absence of detectable antibody to hu14.18 by serology~* More than 28 days since prior autologous stem cell transplantation~  * Prior autologous marrow or stem cell infusion using monoclonal antibody-purged specimens allowed~* More than 1 week since prior growth factors~* At least 7 days since prior nonmyelosuppressive biologic agents~* No prior allogeneic bone marrow or stem cell transplantation~* No concurrent immunomodulating agents~* No concurrent growth factors~Chemotherapy~* More than 3 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered~* No concurrent anticancer chemotherapy~Endocrine therapy~* No concurrent corticosteroids except 100 mg or less of hydrocortisone (or equivalent) as premedication for blood transfusion or treatment for transfusion reaction~  * No other use of systemic steroids~Radiotherapy~* Recovered from prior radiotherapy~* At least 2 weeks since prior local palliative radiotherapy (small port)~* At least 6 months since prior craniospinal radiotherapy~* At least 6 months since prior total body irradiation~* At least 6 months since prior radiotherapy to ≥ 50% of the pelvis~* At least 6 weeks since other prior substantial bone marrow radiotherapy~* Concurrent radiotherapy to localized painful lesions allowed provided at least 1 measurable or evaluable lesion is not irradiated~Surgery~* More than 2 weeks since prior major surgery (e.g., laparotomy or thoracotomy)~* No prior organ allografts~Other~* No concurrent immunosuppressive drugs~* No other concurrent myelosuppressive antineoplastic drugs

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Disease Measurable by Standard Criteria(hu14.18-interleukin-2) (Type: EXPERIMENTAL): Patients with residual/refractory neuroblastoma and readily measurable residual/refractory disease using standard radiographic criteria. Standard radiographic criteria for CT/MRI Lesions will use the definitions of measurable disease from the Response Evaluation Criteria In Solid Tumors (RECIST) from the National Cancer Institute.~hu14.18-Interleukin-2 fusion protein : Given IV
- Disease Eval by MIBG or BM Histology (hu14.18-interleukin-2) (Type: EXPERIMENTAL): Patients with residual/refractory neuroblastoma with disease that is not measurable by standard radiographic criteria, but is evaluable by meta-iodobenzylguanidine (MIBG) scanning and/or by bone marrow (BM) histology.~hu14.18-Interleukin-2 fusion protein : Given IV
- Disease Identified by BM Immunohistochemistry Only (Type: EXPERIMENTAL): Patients with residual/refractory neuroblastoma that do not have disease that is measurable by standard radiographic techniques or evaluable by meta-iodobenzylguanidine (MIBG) scanning or bone marrow (BM) histology, however, disease is identified and quantified by BM immunohistochemistry (\>5 neuroblastoma cells per 1,000,000 nucleated marrow cells).~hu14.18-Interleukin-2 fusion protein : Given IV

Based on this trial design, predict the completion outcome and termination type (if applicable).